ZYME vs MPLT

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 13, 2026

ZYME

37.1
AI Score
VS
ZYME Wins

MPLT

31.4
AI Score

Investment Advisor Scores

ZYME

37score
Recommendation
SELL

MPLT

31score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric ZYME MPLT Winner
Net Income -81.13M -120.86M ZYME
Operating Income -92.55M -128.05M ZYME
ROE -30.2% -34.7% ZYME
ROA -23.4% -32.8% ZYME
Total Assets 346.53M 368.35M MPLT
Cash 41.16M 71.63M MPLT
Current Ratio 5.88 16.52 MPLT
Free Cash Flow -34.53M -96.09M ZYME

Relative Price Performance (Last 90 Days)

ZYME 1M: +5.3% · 3M: +14.3% MPLT 1M: +14.2% · 3M: -57.2%

Current Technical Phase

ZYME

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 45

RSI (14): 45.5 · Price: $26.24

MPLT

Markdown
Sell / avoid

Price below a falling SMA50 (slope -25.7%), weak momentum, RSI 40

RSI (14): 40.1 · Price: $13.00

Fundamentals Snapshot

Metric ZYME MPLT
Market Cap
Forward P/E 22.5 -3.9
Trailing P/E
Revenue (TTM)
Revenue Growth -0.9% 0.0%
Gross Margin -2.5%
Operating Margin -9.2% 0.0%
EPS -2.02 -20.22
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, ZYME is currently the stronger investment candidate, winning 5 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.